Full Report

Know the Business

Blue Moon is a one-category brand (Chinese liquid laundry detergent) riding on 16 consecutive years of category share leadership. Gross margin confirms the brand still has pricing power — around 60%, in line with Colgate. What has broken is distribution: selling and marketing expense climbed from 29% of revenue in FY2020 to 59% in FY2024 before partially unwinding to 53% in FY2025, turning a mid-teens-margin business into a loss-maker. The market is pricing a consumer-staples name at a 6% dividend yield with no debt; the question is whether the channel inflation is cyclical (Douyin tax) or structural (moat erosion).

1. How This Business Actually Works

One brand, one category, one country, sold mostly on the internet. Fabric care is 88% of revenue, China is almost 100% of revenue, and online channels carry 59% of it. The P&L only has three dials that matter: gross margin, selling-and-marketing intensity, and whether customer acquisition on livestream platforms earns a return.

The economic engine is almost pure FMCG: water, surfactant, fragrance, plastic bottle — sold at a branded price. Cost of sales is only 40% of revenue; most of the rest is not manufacturing overhead, it is the marketing tax paid to reach consumers. That makes brand health and channel economics, not factory efficiency, the binding constraint.

**The 89% number.** In FY2025, selling and marketing expense consumed 89% of gross profit (HK$4,468M of a HK$5,021M gross profit pool). In FY2020 it took 45%. The business did not lose pricing power — it lost the ability to reach customers cheaply.

The drivers underneath this line are well-understood inside China FMCG: Tmall and JD traffic got more expensive as Pinduoduo and Douyin pulled volume away, and Douyin itself runs on paid livestream slotting fees and influencer commissions that do not compound like shelf space. A 59% online mix means every point of channel inflation flows straight into operating expenses.

2. The Playing Field

Blue Moon's gross margin is world-class. Its cost structure is not. Against four global household-products peers, Blue Moon sits next to Colgate on gross margin (both ~60%) but an order of magnitude below on operating margin. Every peer converts roughly a third to two-thirds of gross profit into operating income. Blue Moon converts none.

No Results

The peer that matters most is Colgate. Same gross margin profile, same premium-brand-in-a-crowded-category posture, roughly the same channel sophistication — but 15 points of S&M intensity lower and 20 points of operating margin higher. That gap is what "fixed" looks like: a Blue Moon that spent 38% of revenue on marketing instead of 53% would show a mid-teens operating margin today without touching price or volume.

Blue Moon sits alone in the top-right quadrant: premium-priced product, premium-priced customer acquisition. No global peer pays anywhere close to this much to sell what is functionally the same box of surfactant.

3. Is This Business Cyclical?

Not cyclical in the macro sense; very cyclical in the channel sense. Global household-products consumption is famously defensive, and Chinese household volumes did not actually drop during 2022-2024. What is cyclical here is the price of internet distribution. FY2023-FY2024 were the Douyin / livestream-commerce peak: paid traffic costs on short-video platforms tripled while Tmall and JD protected their take rates. Revenue barely moved ($938M → $1,102M → $1,080M), but reported profit collapsed.

The more useful cycle to watch is the Chinese e-commerce channel mix. When Douyin traffic is cheap relative to Tmall, Blue Moon benefits — it over-indexes to online and can flex spend into the cheapest available channel. When the ratio inverts, the P&L hits a wall. The FY2025 improvement (loss narrowed 56% year-on-year) came almost entirely from pulling back paid traffic, not from volume or price.

One structural risk sits under the cycle: Chinese household-detergent volumes are mature. Fabric care revenue fell 3.0% in FY2025, so any margin recovery has to come from lower spend, not scale.

4. The Metrics That Actually Matter

Skip P/E and EV/Sales. For this specific business, four income-statement lines and one market-research rank tell you almost everything.

No Results

What to watch each reporting period, in priority order: selling & distribution expense as % of revenue (directional move drives most of the earnings surprise — a return toward 40% is the bull case, drift back above 55% kills the thesis); gross margin (a break below 55% means pricing power cracked and the story changes); fabric care revenue growth (−3.0% is a warning, a second negative year makes it a demand problem, not a channel problem); cash balance (HK$3.7B at year-end vs HK$10.9B at IPO — still comfortable, no debt, 4.2x current ratio, but the burn is real); and C-BPI rank (a slip to #2 in fabric care is the single most important long-term signal).

5. What I'd Tell a Young Analyst

The temptation with Blue Moon is to score it the way you score Colgate — count segments, admire the brand, project a margin path. Resist that. This is a single-product-single-country company whose income statement is now dominated by one variable: the cost of selling online in China. Everything else is secondary.

The bull case is specific and testable. Gross margin stays around 60%, management takes another 5-8 points out of S&M intensity, and operating margin snaps back to 8-12% on flat revenue. At that level the current market cap looks cheap. The bear case is also specific. Fabric care keeps declining, online traffic stays expensive, and the company has to keep spending 50%+ of revenue just to hold share. In that scenario the 6% dividend is unfunded within two years.

The thing most analysts will miss is that gross margin and market share are still holding. That is the whole bull case — the brand is not the broken piece. If you see gross margin crack or C-BPI slip, you get out; if you see S&M intensity compress two quarters in a row, you get bigger. Don't mistake this for a slow-fade consumer-staples name. It is a binary bet on whether channel cost discipline can be recovered in a market the company does not control.

The Numbers

Blue Moon is a 60%-gross-margin laundry-detergent franchise that has spent its way into two consecutive years of operating losses. Revenue ran from HK$7.0B in FY2020 to HK$8.4B in FY2025 (+4% CAGR), but selling & marketing expense ran from HK$2.0B to HK$4.5B over the same period — from 28.8% of sales to 53.1%. The franchise economics are intact (gross margin has held in a tight 58–64% band for six years); the distribution economics are not. The single metric most likely to re-rate or de-rate this stock is S&M as a percentage of revenue — if it stays in the 50%+ zone the company will keep bleeding cash, and if it normalizes toward 35% the earnings power comes back fast.

Snapshot

Share Price (HK$)

2.96

Market Cap (HK$B)

17.35

Net Cash (HK$B)

3.72

Revenue TTM (HK$B)

8.41

Operating Margin (TTM)

-4.0%

Dividend Yield

6.08

Blue Moon trades at HK$2.96, down 81% from its HK$15.32 first-day close in December 2020. Net cash (HK$3.60B cash + HK$0.11B fixed deposits) equals HK$0.63/share — 21% of market cap — so the entire enterprise value is around HK$13.6B against HK$8.4B of revenue (EV/Sales ≈ 1.6x).

Is the franchise still healthy?

No Results

The franchise is healthy on every dimension that depends on customers buying product (gross margin is a hair below peak), but unhealthy on every dimension that depends on management choices around spend. The balance sheet makes the self-inflicted wound survivable — Blue Moon has no debt and still has HK$3.7B of liquid cash after losing HK$1.1B operating pre-tax over two years. At current burn it can fund 2–3 more years of losses before the balance-sheet thesis breaks.

Revenue and earnings power — six-year view

Revenue has grown in a narrow HK$7.0–8.6B band since the 2020 IPO — scale is not the problem. The drama is underneath: operating margin fell from 25% to -12% in four years while gross margin barely moved. That shape says the cost of keeping and growing shelf presence online has exploded, not the cost of making product.

The expense that broke the model

**Critical chart.** Selling & marketing expense as a share of revenue doubled from 28.8% in FY2020 to 59.0% in FY2024, before a first step down to 53.1% in FY2025. Every other line item is sideways. This single chart explains the stock.

From FY2020 to FY2024 Blue Moon's S&M spend more than doubled in absolute terms (HK$2.0B → HK$5.0B) while revenue only grew 22%. The incremental HK$3B of distribution and promotion spend bought almost nothing — revenue over FY2023–FY2024 was HK$7.3B → HK$8.6B. The FY2025 pullback (HK$5.0B → HK$4.5B) is the first time management has visibly held the line; revenue dipped 1.7% but losses shrank 56%.

Cash generation — the balance is what's real

The cash trajectory is blunt: HK$10.9B at IPO, HK$3.6B six years later. FY2023 was the single worst year (cash down HK$3.4B — mixing operating bleed with working-capital drains and dividend). FY2024 was deceptively positive (cash up HK$874M) on a working-capital release. FY2025 resumed the burn at HK$1.6B as losses continued and management restored a dividend.

Reported cash flow detail is limited — HKEX annual results announcements publish a condensed set — but the change-in-cash line is unambiguous: roughly two-thirds of the IPO proceeds have been consumed in five years.

Balance sheet — fortress on one side, melting ice cube on the other

Total liabilities sit at HK$1.8B — mostly trade payables and accruals, no interest-bearing debt. Equity has fallen from HK$11.7B to HK$7.5B (-36%), and accumulated profits flipped from a HK$1.7B positive balance to a HK$455M deficit in FY2025. The fortress is unambiguous but it's being spent, not grown.

Stock price — 81% drawdown since listing

Two legs down: the re-rate from bubble IPO multiples (2021), then the earnings cut as the S&M problem appeared (2022–2023). A brief 2024 bounce coincided with management signalling cost discipline; the stock has since round-tripped below HK$3 as the FY2025 results confirmed the recovery is slower than hoped.

Valuation vs its own history

Price / Book (now)

2.31

P/B — 5y avg

2.08

Price / Sales (now)

2.06

P/S — 5y avg

2.66

Earnings multiples are not meaningful — the company is loss-making. On book and sales, Blue Moon trades near its 5-year averages, which is what you'd expect when the franchise is functional but the margin outlook is uncertain. The FY2023 trough (P/B of 1.22x, P/S of 1.73x) is what the market priced when losses were still a surprise; the current level already embeds some recovery optimism.

Peer comparison — the outlier on operating leverage

No Results

Blue Moon has the best-in-class gross margin but the worst operating margin in the peer set. The gap between 59.7% gross and -4.2% operating is roughly 64 percentage points of opex — almost exactly double what Colgate-Palmolive runs on a similar gross-margin profile (44 points). If Blue Moon's opex ran at Colgate's level of sales, FY2025 operating income would be about HK$1.3B of profit instead of HK$355M of loss. That's the size of the prize if the S&M correction sticks. (CL and CLX show distorted ROE figures because aggressive buybacks have shrunk their book equity; ignore those two rows for equity-return comparison.)

Fair value framework

Consensus analyst price targets cluster between HK$2.27 and HK$2.60, low end HK$1.61, high end HK$3.40 — effectively neutral on current price. A scenario-based view is more useful than a point estimate given earnings are negative.

No Results

At HK$2.96 the market is pricing somewhere between the bear and base scenarios. The net-cash cushion (HK$0.63/share, ~21% of market cap) makes the bear case tolerable — equity is unlikely to go to zero absent sustained multi-year burn. The bull case requires 700+ basis points of operating margin recovery, which the FY2025 loss narrowing hints at but has not delivered.

Bottom line

The numbers confirm that Blue Moon still owns a premium Chinese laundry-detergent franchise: gross margin is peer-leading, the brand commands shelf at 60% gross, and the balance sheet has zero debt and HK$3.7B of cash. The numbers contradict the popular narrative that this is a structurally broken business — the gross margin has held through the collapse, which says the problem is distribution and marketing cost, not demand or pricing. What to watch next: FY2026 interim S&M as a percent of revenue. If it prints below 48%, the turn is real and the operating-margin recovery arithmetic goes fast; if it stays at 53%+, management has not actually regained control of the cost base and the cash runway becomes the story.

The People

Governance grade: C+. Blue Moon is a family-controlled founder business where the husband–wife co-founder duo (Chairman PAN Dong + CEO LUO Qiuping) own roughly 76% of the shares. Alignment on paper is maximal, but independence is at the Hong Kong Listing Rules floor, minority voice is thin, and the public float has quietly concentrated below the default 25% — prompting the Company in January 2026 to adopt HKEX's Rule 13.32B alternative threshold. Balance-sheet stewardship (net cash, non-dilutive share awards, zero borrowings) is the redeeming story.

Governance Grade

C+

Founder-Family Stake (%)

76.0

Board Independence (%)

37.5

Public Free Float (%)

21.15

The People Running This Company

Blue Moon has no professional-CEO layer separating the founder family from operations. The Chairman and the CEO are husband and wife, both are co-founders, and between them they also hold the Chief Technology Officer and COO-adjacent roles. A third Luo (LUO Dong) also sits on the Executive Directors' bench, so the executive board is effectively five names of whom at least three are family-adjacent insiders.

No Results

**Family-density risk.** Three of the five executive directors share bloodlines or marriage ties (PAN Dong, LUO Qiuping, LUO Dong). Succession planning is not disclosed; the CEO is 62 and the Chairman is 60. An unexpected departure would concentrate operational authority on POON (CFO) and XIAO (COO) — neither of whom has a public track record outside Blue Moon.

What They Get Paid

Per-director cash-and-incentive emoluments are published in the full Annual Report under HKEX Appendix C1 — the March 2026 results announcement does not repeat them. What is disclosed is the overall employee cost envelope (down 6.4% year-on-year as losses narrowed) and the share-plan mechanics, which are the compensation items that actually matter for shareholders. Pay signal is therefore legible through the share plans and the auditor-fee ratio, not through a CEO-pay table.

No Results

**Non-dilutive incentive design.** Both share-award plans are satisfied out of *existing* shares purchased in the open market, not newly issued stock. That makes Blue Moon's ~396m cumulative share grants (6.8% of shares outstanding) effectively a return-of-capital mechanism rather than a dilutive drain on minority economics. This is one of the cleanest shareholder-friendly pay designs in the HKEX consumer-staples space.

The audit-fee ratio also tells a small but useful story. Non-audit fees to auditor PricewaterhouseCoopers fell from HK$2.107m (FY2024) to HK$1.102m (FY2025), cutting the non-audit-to-audit ratio from 61% to 31% — moving toward auditor-independence best practice rather than away from it. Audit cost itself ticked up just 2% to HK$3.56m (~$0.46m), proportionate to an HK$8.4B-revenue consumer-products business.

Are They Aligned?

This is where Blue Moon's grade earns its asterisks. Economic alignment is textbook — the founder family has roughly $1.7B of personal market value on the tape — but control alignment sits in tension with minority alignment on three specific axes: free-float shrinkage, option-exercise optics, and the dividend-vs-losses debate.

**Float concentration decision — 8 January 2026.** The Company adopted HKEX Rule 13.32B's alternative free-float threshold (market cap of at least HK$1bn AND at least 10% public hands), replacing the default 25% minimum. This is a concession to a shrinking public register and functionally locks in minority dilution of voting influence. The move is legal and disclosed, but it is the single strongest signal that the founder family intends to keep control tight — not broaden ownership.

Option exercise and insider dealing. During FY2025, 987,850 share options were exercised at a weighted-average price of HK$3.76 (FY2024: 110,000) — against a share price that spent most of the year between HK$2.50 and HK$4.34. That is in-the-money exercise behaviour in the upper half of the trading range, suggesting participants exercised into strength rather than distress. Aggregate-only disclosure in the results announcement masks which directors exercised; the detailed Directors' Interests notifications on HKEXnews would close that gap. No company or subsidiary buybacks of listed securities occurred in FY2025.

Related-party transactions. The balance sheet shows just HK$412,000 (~$53,000) due to a related company at 31 December 2025 — essentially a rounding error in an HK$9.35B balance sheet. This is unusually clean for a Chinese family-controlled issuer, where related-party bloat is a standard concern. Credit where due.

Capital-allocation posture. FY2025 still printed an HK$312m net loss, yet the Board resumed the dividend (HK8 cents interim + HK10 cents final = HK18 cents total, a 6.08% trailing yield). With HK$4.88B net cash and zero borrowings, paying out from accumulated reserves is defensible — but it is worth naming: the founder family receives roughly 76% of that dividend, making this simultaneously a pro-minority cash return and a pro-founder wealth-preservation move.

Skin-in-the-Game Score (1-10)

Board Quality

No Results

**Independence is at the Code floor.** Three of eight directors (37.5%) are classified Independent Non-Executive — one-third is the HKEX minimum. Investor-grade boards in consumer staples typically run at 50% or more independence. The board structure legally clears the bar but offers very limited counter-weight against a 76%-owner Chairman. Committee memberships (Audit / Remuneration / Nomination) are disclosed only in the full Annual Report, not in the results announcement reviewed here.

Auditor and compliance hygiene. PricewaterhouseCoopers has signed the accounts; the audit-vs-non-audit fee ratio improved materially in FY2025 (see pay section). All directors confirmed Model Code compliance. The company self-assesses as fully compliant with Appendix C1 of the HKEX Corporate Governance Code. The Chamber of Hong Kong Listed Companies granted Blue Moon a Corporate Governance Excellence Award for 2024-2025 and an ESG Honourable Mention in 2025 — modest positive third-party validation.

Missing capability. The disclosed skill distribution across the INEDs (based on the results announcement — full AR bios would add colour) is thin on publicly named capital-markets or M&A expertise. For an HK$17.3B-market-cap consumer-staples issuer with HK$4.9B of excess cash, the capital-allocation committee muscle is concentrated inside the executive bench, not checked by an outside voice.

The Verdict

Governance Grade

C+

Why C+ and not B. The positives are real: ~76% founder economic stake, non-dilutive share-award design, de minimis related-party exposure, net-cash balance sheet, clean auditor relationship, resumed dividend. These are the markers of a founder who still treats the business as personal wealth rather than a vehicle for extraction. Blue Moon avoids most of the specific pathologies that earn Chinese HKEX-listed consumer companies a D or F.

Why not B+ or higher. Four items keep the grade capped: (1) a husband–wife executive chairman/CEO pair removes the practical chairman-CEO separation that exists on paper; (2) a third executive director shares the CEO's surname with no disclosed independence test; (3) the public free float has drifted below the 25% default, triggering the Rule 13.32B alternative-threshold adoption in January 2026 — a defensive governance choice, not an expansive one; (4) INED headcount sits exactly at the Listing Rule floor rather than at investor-grade best practice.

What would move the grade. Upgrade catalysts: (a) a fourth INED with disclosed capital-markets or consumer-M&A expertise; (b) per-director pay disclosure adopted pre-full-AR; (c) a buyback program of listed securities (not just share-plan market purchases) signalling capital-allocation discipline to minorities. Downgrade catalysts: (a) any enlargement of the related-party line, however modest; (b) insider exits above the 987,850-option-exercise scale without offsetting reinvestment; (c) further shrinkage of the public float toward the 10% Rule 13.32B floor.

The Full Story

Blue Moon came public in December 2020 telling a simple story: dominant brand, expanding online-to-offline distribution, deepening rural penetration, premium margins. Between FY2021 and FY2024 that story fractured: revenue growth stalled, profit fell every single year, then flipped to a HK$749M loss — the single worst result since listing — driven not by collapsing gross margins but by a 56% one-year spike in selling and distribution spend. Management recast the blow-up as a "strategic investment" in the Zhizun concentrated-detergent product line, quietly walked back the original IPO use-of-proceeds, extended the spending timeline three years, and in FY2025 cut advertising hard — losses narrowed 56% but revenue went flat, exposing the investment as fragile rather than compounding. The brand is still #1 in China on most measures; the capital discipline, the guidance, and the original growth thesis are not.

From IPO peak (HK$19.16, Jan 2021) to the FY2025 reporting year, the share price fell roughly 85% — bottoming near HK$1.68 in early 2024. The financial story below explains why.

1. The Narrative Arc

Four inflection points define the arc. FY2021 exposed the first gap: revenue rose 8.6% but profit fell 22.5% as raw material costs climbed and selling expenses jumped 18.6% to defend share. FY2022 introduced non-HKFRS "adjusted EBITDA" disclosure to strip out FX losses — a presentation choice that quietly conceded GAAP profitability was deteriorating. FY2023 was the first outright revenue decline (-7.8%) alongside a 46.8% profit collapse; management began de-risking key-account receivables. FY2024 was the rupture: HK$749M loss and a management narrative that reframed the blow-up as deliberate — "strategic investments in bringing the comprehensive series of products… to reach more consumers." FY2025 was the walk-back: expenses were cut, the loss narrowed, but the promised sales growth from the 2024 investment did not materialize.

2. What Management Emphasized — and Then Stopped Emphasizing

Topic frequency across five annual filings. Higher values = greater emphasis; dashes mark themes quietly dropped.

Three patterns stand out. The Supreme-brand concentrated detergent — featured prominently in the FY2020 prospectus and still referenced in FY2021 as a sales-return drag — vanished entirely from the FY2022 report onward; management never reconciled what became of that product line. Laundry services was an explicit IPO use-of-proceeds category that management stopped discussing by FY2024 and then eliminated operationally when they reallocated capital in March 2025. Knowledge-based marketing and Zhizun moved in lockstep from barely-mentioned in FY2021–22 to the dominant motifs in FY2024–25 — the pivot from "we sell detergent" to "we educate consumers about scientific washing" coincides exactly with the period when margins were collapsing.

3. Risk Evolution

The risk discussion in MD&A reveals what management was actually worried about each year, in their own emphasis.

The risk register has rotated almost completely. Raw materials and COVID — the 2021–22 preoccupations — are now effectively retired. FX flared in FY2022 (and prompted the non-HKFRS adjusted EBITDA disclosure) and again in FY2024. Key-account credit risk peaked in FY2023 when management explicitly cut sales to credit-based customers; that channel has since shrunk from 14% of revenue (FY2021) to 4% (FY2025). The two risks rising over time — channel shift to Douyin/live-stream and cash discipline — are the unresolved ones heading into FY2026.

4. How They Handled Bad News

Management's handling of disappointments followed a pattern: absorb, reframe, measure by a new yardstick.

**The FY2024 reframe.** Before the loss, management guided "further improve financial conditions and raise operational efficiency and better control the operational costs" (FY2021 outlook). After the loss, the exact same spending was described as "strategic investments… will contribute to the Group's long-term sales growth." The spend was not reversed; its label was.

Three episodes illustrate the technique.

FX losses in FY2022. Net profit fell 39.7% with roughly half the drop coming from a HK$156M foreign-exchange loss on offshore RMB deposits. Management's response was to introduce an unaudited "adjusted EBITDA" that excluded FX, explicitly to "eliminate the potential impact of foreign exchange losses/(gains) which the Group consider to be non-indicative of the performance of the business." The non-HKFRS disclosure was then dropped in FY2023 when it would have made results look worse, not better.

Revenue decline in FY2023. HK$ revenue fell 7.8%. Management's framing pivoted to RMB-terms (-2.9%) and to second-half RMB growth (+4.5%), de-emphasizing the presentation-currency print.

The FY2024 loss. A HK$749M loss was described as an intentional long-term investment — yet in the same filing management reallocated HK$2.6B of unused IPO proceeds away from production capacity ("no imminent requirement to utilise a substantial portion of capital") toward more marketing, and extended the use-of-proceeds timeline from end-2025 to end-2028. A "strategic investment" that the capital plan reclassifies mid-stream is difficult to distinguish from a belated course correction.

5. Guidance Track Record

Only material promises that bore on valuation, capital allocation, or credibility are included.

No Results

Credibility score: 3.5 / 10. The brand franchise is real; the consumer rankings have held for 15+ years; gross margin has stayed in a tight 58–62% band. But at the capital-allocation and guidance layer, the record is poor: the original IPO plan was rewritten, the flagship "Supreme" product quietly disappeared, the laundry-services priority was abandoned without acknowledgment, and management's FY2024 reframe ("strategic investment") was contradicted the following year when flat revenue showed the spending hadn't earned durable growth. Investors who took FY2021–22 guidance at face value have been repeatedly asked to reinterpret past promises in light of later events.

Credibility Score (1-10)

6. What the Story Is Now

FY2025 Revenue ($M)

$1,080

FY2025 Net Income ($M)

-$42

FY2025 Cash ($M)

$477

Drawdown from IPO Peak (%)

What has been de-risked. The FY2024 spending spike proved compressible: the FY2025 cost cuts landed without obvious brand damage, and the Zhizun concentrate line was productive enough to keep losses narrowing. Key-account credit exposure is now small. FX exposure is managed via USD deposits. Gross margin has been durable through the whole episode.

What still looks stretched. Three things. First, revenue growth: FY2025 was flat, and the entire FY2024 "strategic investment" has not demonstrably produced a compounding sales base. Second, cash: the deposit pile has fallen from HK$10.9B at IPO to HK$3.7B — a two-thirds reduction in five years against continuing operating losses and dividend outflows. Third, the capital plan: the reallocation of unused IPO proceeds extended delivery from 2025 to 2028, and a portion was redirected into the same selling-expense bucket that has not yet earned its keep.

What the reader should believe. The brand is genuine and the rankings are verifiable; management is competent at cost discipline when forced to apply it; and the concentrated-detergent pivot is real product innovation, not marketing fiction. What the reader should discount. Any language about "strategic investment", "long-term sales growth" from advertising, or the confidence-in-China-cleaning-market refrain — the first two were directly falsified in FY2025, and the third is a background condition, not a plan. The FY2026 test is straightforward: can revenue grow from here without a return to HK$5B+ in selling expense?

**Bottom line.** Blue Moon today is a franchise with intact brand equity but a five-year track record of capital destruction, rewritten guidance, and narrative relabeling. The FY2025 cost reset is the most credible signal in years — but it is not, by itself, evidence that growth resumes.

What's Next

The near-term calendar is dominated by a single print — H1 FY2026 interim results in August 2026. Everything else is context around it. Both Bull and Bear name that date as their primary trigger.

Dated catalysts the market will actually trade:

August 2026 — H1 FY2026 interim results. The single decisive print. Three numbers carry the entire tape: S&M as a percent of revenue, YoY revenue growth, and gross margin. Bull needs S&M at or under 48% with flat-to-up revenue; Bear needs S&M at or over 50% or negative YoY revenue. A death cross printed 2025-09-26 and price sits below the 200-day SMA — the tape is pre-positioned for whichever way the print cuts.
June 2026 — 618 Shopping Festival. Peak mid-year Chinese e-commerce window. Promo intensity from Liby, P&G, and Unilever sets the pricing floor Blue Moon must defend. Channel-check chatter in early July previews the H1 S&M read.
November 2026 — Singles Day (11.11). Largest single selling day of the year. Post-festival commentary hints at H2 S&M ratio. If Blue Moon has to re-open the spigot for 11.11, the FY26 full-year S&M print will land above FY25.
March 2027 — FY2026 annual results. Full-year confirmation. The dividend decision is the second read — whether the FY25 HK18c hike repeats on a further-shrunken cash pile, or management quietly cuts back.
Ongoing — governance signals. Any further reallocation of unutilized IPO proceeds (current plan runs to end-2028), any new non-HKFRS disclosure line, or any related-party transaction. Management has a history of introducing and retiring adjusted measures when convenient.

No sell-side consensus was locatable for this micro-float HK-listed name, so the reader's own prior is the benchmark. There is effectively one catalyst that matters — August 2026.

For / Against / My View

Bull and Bear have each written their strongest case. Below are the three sharpest points from each side, the direct tensions where they read the same fact in opposite directions, and where the weight falls.

For

**1. Gross margin held through the storm.** Product economics never broke — the collapse in reported earnings is a discretionary S&M spend problem, not a moat problem. Blue Moon is still the #1 liquid laundry detergent in China for 16 consecutive years and prices like it.

Evidence: gross margin stayed in a 57.8–64.5% band across FY2020–FY2025 even as operating margin fell from +25% to −12%; FY25 GM of 59.7% is peer-leading vs Colgate 60.1%, P&G 51.2%, Church & Dwight 44.7%, Clorox 45.2%.

**2. The S&M cost reset is already landing.** FY2025 S&M fell from 59.0% to 53.1% of revenue, absolute S&M dropped HK$5.05B → HK$4.47B, the operating loss narrowed 56% (HK$1.00B → HK$355M), and gross margin did not crack with the cuts. That is the turn signal the market is not yet paying for.

Evidence: Numbers "sm_spend" and "revenue_income" tables; Business §1 waterfall; Story §6 — "FY2025 cost reset is the most credible signal in years."

**3. Net cash floor plus a real, growing dividend.** HK$3.72B of cash, zero interest-bearing debt, equity HK$7.5B. Net cash alone is HK$0.63/share — 21% of the HK$2.96 market price. Dividend hiked to HK18c in FY25 (+80% YoY) for a ~6.1% yield, paid by founders who own 76% alongside minorities. The bear case has a hard asset-value floor within 25% of spot.

Evidence: Numbers "snapshot" and "bs_composition"; People "capital_allocation"; ownership 76% insider + 9% Hillhouse.

Bull Price Target (HK$)

5.00

Implied Upside vs HK$2.96

69%

Timeline (months)

Primary catalyst (Bull): FY2026 interim results (Aug 2026) printing S&M ≤48% of revenue with revenue flat-to-up — confirms the FY25 cut is a trajectory, not a one-off. Disconfirming signal: S&M back above 52% OR gross margin breaking below 55%.

Against

**1. The "strategic investment" is already falsified.** Management spiked selling & distribution from HK$3.2B in FY23 to HK$5.0B in FY24 — a 56% jump branded "strategic investments… will contribute to the Group's long-term sales growth." FY25 revenue then went *down* 1.7% on the pulled-back spend. The incremental HK$3B of S&M poured on FY20–FY24 bought 22% total revenue growth — zero operating leverage.

Evidence: Story (credibility = 3.5/10, "strategic investment" outcome: Not supported); Numbers (S&M 28.8% → 59.0% of revenue FY20–FY24, revenue band HK$7.0–8.6B flat); Business ("cost-to-acquire in Chinese e-commerce has never gone back down structurally").

**2. A dividend paid out of a melting ice cube.** IPO cash at Dec-2020: HK$10.9B. FY25 closing cash + FDs: HK$3.7B. Two-thirds of IPO proceeds consumed in five years while the business lost HK$1.1B pre-tax over FY24–FY25 and equity fell 36%. Against that backdrop management hiked the dividend 80% to HK18 cents (~6% yield), funded entirely from the shrinking cash pile. Cash runway at FY25 burn rate: ~2.3 years.

Evidence: Numbers (cash trajectory HK$10.9B → HK$3.6B + HK$112M FDs; FY25 net change −HK$1.6B); People (DPS HK$0.10 → HK$0.18, zero buybacks); Story (operating losses HK$1.0B FY24, HK$355M FY25).

**3. Governance is rigged — minorities own no decision.** Chairman Pan Dong and CEO Luo Qiuping are husband-and-wife co-founders controlling ~76% of shares. The eight-person board splits 5–3 executive vs. independent — any simple-majority resolution passes with the family alone. In January 2026 Blue Moon moved to Rule 13.32B (≥10% free float); the company now hovers at the 10% floor. Per-director emoluments are absent from the results announcement.

Evidence: People (76% founder stake, board 5–3 math, Rule 13.32B adoption Jan 2026, chair/CEO cosmetic separation, per-director pay absent from results announcement).

Bear Downside Target (HK$)

1.80

Implied Downside vs HK$2.96

-39%

Timeline (months)

Primary trigger (Bear): H1 FY26 interim results (Aug 2026). S&M ≥ 50% of revenue OR revenue negative YoY confirms the FY25 cost reset was cosmetic. Cover signal: H1 FY26 S&M under 45% AND revenue +3% YoY in the same period — the only combination that invalidates the structural-channel-cost argument.

The Tensions

Bull and Bear disagree on three specific data points — not on different facts, but on how to read the same ones. Each tension names the print that resolves it.

1. The FY2025 cost reset — discipline landing, or a smaller business?

Bull says: S&M fell from 59.0% to 53.1% of revenue, absolute spend dropped HK$581M, the operating loss narrowed 56%, and gross margin did not crack — that is discipline proving itself. Bear says: revenue fell 1.7% in the same year, so the cut was not operating leverage but a smaller, cheaper business — a brand that needs the spigot to hold flat volume is not cost-resetting, it is de-scaling. Both cite the same numbers: FY25 S&M −HK$581M, revenue −1.7%, operating loss HK$1.00B → HK$355M. This resolves on H1 FY2026 interim results (August 2026) — specifically whether S&M prints at-or-under 48% with revenue flat-to-up (Bull) or at-or-over 50% or negative YoY (Bear).

2. The net cash pile — floor or melting ice cube?

Bull says: HK$3.72B of cash (HK$0.63/share, 21% of market cap) with zero debt is a hard asset-value floor, and the HK18c dividend at ~6.1% yield is real income paid by founders with 76% aligned ownership. Bear says: IPO cash has fallen from HK$10.9B to HK$3.7B — two-thirds consumed in five years while the business lost HK$1.1B pre-tax over FY24–FY25 — and the 80% dividend hike is liquidation of the IPO pile, not a signal of operating strength. Both cite the same trajectory: HK$10.9B (2020) → HK$3.7B (2025); FY25 net cash change −HK$1.6B; DPS raised to HK18c. This resolves on FY2026 operating cash flow — whether it covers the dividend without further drawing down the deposit pile.

3. The 76% founder stake — alignment or capture?

Bull says: founders own alongside minorities at ~76%, incentives are identical, and the dividend flows to the same pocket as minority shareholders. Bear says: the husband-and-wife Chair/CEO with 5–3 executive board math means any resolution passes without independent veto, and the January 2026 move to Rule 13.32B (10% float minimum) signals tolerance for further concentration — alignment of economics is not alignment on governance decisions. Both cite the same structure: 76% Pan Dong / Luo Qiuping combined stake, 5–3 board composition, Rule 13.32B adoption. This resolves on the next discretionary governance act — either a credible buyback or a public S&M guidance commitment (bull signal), or a related-party transaction or further float reduction (bear signal).

My View

I'd lean cautious — the Against side is heavier, and the reason is Tension 1. The natural reading of FY25 is the one Bear gives: cut S&M by HK$581M, revenue fell 1.7%. Brands that can grow without the spigot don't usually need the spigot, and that reading is reinforced by a 3.5/10 credibility score on past guidance and a five-year track record where every flagship initiative (Supreme, laundry services, the FY24 "strategic investment") has been quietly retired or falsified. The Bull's gross-margin-intact argument is real but only proves that if channel economics normalize the business works — the FY24–FY25 evidence is that they have not. I'd pass today and wait for the August 2026 interim. The one data point that would flip the view: S&M at or under 48% of revenue and revenue flat-to-up YoY in the same H1 FY26 print — the combination of discipline with preserved share is the only outcome that contradicts the structural-channel-cost reading.

What the Internet Knows

The Bottom Line from the Web

The filings say "loss narrowing"; the web adds two things the filings cannot. First, management launched a ~10% share buyback on 2026-03-27 and resumed the dividend one day after reporting a second consecutive annual loss — an aggressive capital-return stance out of step with reported profitability. Second, every independent valuation model we found (Simply Wall St DCF HK$1.59–1.75, Alpha Spread HK$1.58, Simply Wall St community fair value HK$2.54) sits below the current HK$2.88–3.00 share price, while 2 of the 3 external P/S screens flag the stock as richly valued vs peers at 0.5–1.1x. Sell-side coverage has gone silent since UBS's last note in August 2022, leaving the name essentially uncovered.

What Matters Most

On 2026-03-27, Blue Moon commenced an equity buyback plan authorizing up to 586,313,175 shares — roughly 10% of issued share capital — under the mandate approved at the 2025 AGM (MarketScreener news log, 2026-03-27). Paired with the resumed dividend (final dividend for FY2025 payable 2026-06-11) and the 2026-04-16 "Strong Economic Results" announcement citing average annual free cash flow of US$77M using consensus prices, management is publicly doubling down on capital return despite a second consecutive annual loss.

Bullish signal — insider conviction via corporate action: the 10% buyback authorization immediately after the results print is the strongest tangible commitment the founder family has made during the drawdown. Pan Dong already owns 73.78%; the buyback concentrates her economics further while setting a floor for outside holders.

Source: https://www.marketscreener.com/quote/stock/BLUE-MOON-GROUP-HOLDINGS–119080091/

2. Every independent DCF fair value estimate we found sits below the current price

Three different third-party valuation models independently arrived at fair values 40–60% below the HK$2.88–3.00 market price. This is the single biggest disconnect between price and external models.

No Results

Sources: Alpha Spread (alphaspread.com/security/hkex/6993), Simply Wall St (simplywall.st/stocks/hk/household/hkg-6993), Investing.com consensus, Stockopedia.

Red flag — valuation gap: the trailing P/S of 1.9–2.0x vs peer average 0.5x and Asian Household Products industry 1.1x means the overvaluation signal shows up on a simple multiple, not just modelled DCF. Simply Wall St: "The market is assigning Blue Moon a higher revenue valuation than many alternatives that could be available if sentiment shifts and valuations move closer to the fair ratio level."

3. Sell-side has abandoned the name — last major-bank note was UBS in Aug 2022

No Goldman, Morgan Stanley, or JP Morgan coverage surfaced in the search results. The most recent sell-side price-target adjustment is UBS trimming from HK$6.33 to HK$6.17 on 2022-08-30 (MarketScreener analyst history). That target is now roughly double the current price and is 3+ years stale. Investing.com reports only six analysts still publish a number (3 Buy / 0 Hold / 3 Sell, neutral consensus, average HK$2.40–2.60).

The coverage vacuum is material for a HK$17B-market-cap consumer-staples name. Thin coverage means the price discovery mechanism relies on retail and index flows, not on fundamental analyst work. It also means the consensus numbers are more susceptible to noise than for a well-covered peer.

Source: https://www.marketscreener.com/quote/stock/BLUE-MOON-GROUP-HOLDINGS–119080091/

4. Chief Supply Officer LUO Dong earns 4.6× the CEO — the compensation outlier of the board

Simply Wall St's management table shows Dong Luo (Executive Director & Chief Supply Officer) at HK$36.82M total compensation vs CEO Qiuping Luo at HK$7.99M, COO Haishan Xiao at HK$5.19M, and CFO Kwok Leung Poon at HK$6.88M. Chairwoman Pan Dong receives only HK$618K in cash — her 73.78% stake (~US$1.59B per 2026-03-30 MarketScreener valuation) is the real pay. Dong Luo also holds 1.08% (63.4M shares, ~US$23M).

Governance red flag — two signals in one: (a) the Chief Supply Officer out-earning the CEO by 4.6× is unusual for any listed consumer-staples company; (b) surname overlap with CEO Luo Qiuping (husband of Chairwoman Pan Dong) — combined with his 1.08% personal stake, executive director seat, and 20-year tenure — is consistent with Sherlock's hypothesis that Luo Dong is a family relation, which would put 3 of 5 executive director seats in the founder family. Web coverage does not explicitly confirm or deny the family tie, only surname evidence.

Sources: https://simplywall.st/stocks/us/household/otc-blum.y/blue-moon-group-holdings/management, https://www.bloomberg.com/profile/person/22120404

5. Free float is 21.15% — above the new 10% alternative threshold but reduced since IPO

MarketScreener reports free float at 21.15%; the founder/family and Tricor Trust block totals roughly 78.9% (Pan Dong 73.78%, Tricor Trust 3.96%, Luo Dong 1.08%, Poon Kwok Leung 0.20%). The HK$17B market cap easily clears the new HK$1B Alternative Threshold introduced by HKEX on 2026-01-01 under Rule 13.32B(2), so there is no immediate compliance risk, but Blue Moon must now report its public float in every monthly return and justify any reliance on the alternative threshold.

Context — the new rules: HKEX's 2026-01-01 reforms (Charltons, Morgan Lewis, Bird & Bird briefings) allow a ≥10% public-float floor provided public-hand market value is ≥HK$1B, calculated on a rolling 125-trading-day VWAP. The buyback does not put Blue Moon at risk of breaching either the 25% initial float or the 10% alternative, but the family block's room to add to its stake via the buyback program is real.

Sources: https://www.charltonslaw.com/new-ongoing-public-float-requirements-for-hkex-listed-companies-from-1-january-2026/, https://www.morganlewis.com/pubs/2025/12/hkex-publishes-conclusions-on-proposed-amendments-to-listing-rules

6. Dividend yield ~5.8–6.7% — but not covered by earnings or cash flow

FT reports dividend yield 6.14%; MarketScreener 6.69%; Simply Wall St 5.78%. All three note the payout sits alongside a HK$328.9M trailing net loss and weak FCF coverage. Simply Wall St flagged in its 2026-03 update: "Ongoing losses over the past five years, growing at 61.1% per year, contrast with a relatively high yield… how long can a dividend sit above earnings and free cash flow without some form of reset?"

Red flag — dividend sustainability: paying a 6% yield plus buying back 10% of stock while reporting losses requires either (a) substantial off-balance-sheet cash generation that doesn't show up in GAAP, or (b) drawing down the existing cash pile (MarketScreener: net debt ≈ −HK$4.88B / +HK$623M cash net). The 2026-04-16 "US$77M average FCF" framing is management's answer; the market hasn't accepted it, based on the 21.15% free float currently trading at DCF-negative prices.

Sources: https://simplywall.st/stocks/hk/household/hkg-6993, https://markets.ft.com/data/equities/tearsheet/summary?s=6993:HKG

7. H1 2025 was worse than 2H 2024 — the catalyst behind the Sep 2025 sell-off

Per Simply Wall St's half-year decomposition: H1 2024 EPS loss HK$0.120, 2H 2024 EPS loss HK$0.0159, H1 2025 EPS loss HK$0.082. H1 revenue slipped from HK$3,131.2M (H1 2024) to HK$3,036.8M (H1 2025). In other words, after a visibly improving 2H 2024, H1 2025 results reported on 2025-08-21 showed the loss re-widening vs the prior half — the likely catalyst for Tech specialist's flagged 22× volume spike and death-cross cluster in mid-September 2025.

Historical pattern: the sequential improvement 2H 2024 → H1 2025 did not hold. Management's January 2026 guidance for "at least halved" FY loss required a very strong 2H 2025 to catch up — which the FY2025 final number (HK$328.9M loss vs HK$749M) confirms was delivered. But the H1/H2 volatility is unusual for a staples business and warrants scrutiny.

Source: https://simplywall.st/stocks/hk/household/hkg-6993/blue-moon-group-holdings-shares/news/blue-moon-group-holdings-sehk6993-eps-loss-deepens-and-tests

EqualOcean's 2020 analysis (still the most detailed competitive piece available) documents Blue Moon's laundry-liquid share peaking at over 50%, declining to 24.4% in 2019, with Liby less than 2 percentage points behind. Average fabric-care price per kg dropped 5.46% YoY in 2019. Blue Moon launched concentrated liquid detergent in 2015 but was still a year behind Ariel and Liby on detergent pods (2017 vs 2018). Zhizun's MSRP of RMB130 was discounted to RMB60 on JD during promotions, actively undermining its own premium positioning.

The moat is narrower than the 24.4% #1 share suggests: #1 with Liby close behind, in a category growing low-single-digit (China fabric-care CAGR 4.8% 2015–2019 per Frost & Sullivan), against P&G / Unilever / Kao / White Cat from the premium side and Liby / NIC from the mass side. Price-per-kg compression is evidence of a price war, not a defended premium.

Source: https://equalocean.com/analysis/2020092614871

9. Hillhouse / HHLR Advisors stake holds at 8.99% — no recorded sell-down

Bloomberg / MarketScreener show HHLR Advisors Ltd (Hillhouse Capital's public-markets arm, run by Lei Zhang) holding 8.994% (527.4M shares, ~US$194M). Stockzoa's 13F tracker shows Hillhouse's broader public portfolio had −16.42% performance in Q4 2025 and is concentrated in PDD/BABA/ONC — but no Blue Moon reduction is reported. Hillhouse has been the only external institutional shareholder of size since the 2010 US$45M pre-IPO investment.

Bullish signal — no evidence of Hillhouse exiting. Given HHLR's own portfolio pressure, a forced sale would be a meaningful overhang; we do not see one in the coverage available.

Sources: https://www.bloomberg.com/profile/company/1301451D:HK, https://stockzoa.com/fund/hillhouse-capital-advisors-ltd/

10. Zhizun's premium-concentrate thesis is real, but validated mainly by pre-IPO material

The AIM2Flourish innovation profile (Case Western Weatherhead, Yuhonghao Wang) is the most substantive English-language description of Zhizun we located: 47% surfactant vs industry 25%, press-pump dosing, ~2× price of non-concentrated detergent, distribution in 11,000+ supermarkets and 120,000+ retailers across 300+ cities. But the piece is pre-IPO era, and the only recent update from the web confirming current Zhizun mix share is the 2026-01-13 Simply Wall St summary referencing management's own line about "continued investment in… concentrated liquid laundry detergents and foaming body wash." No independent 2025 share data for Zhizun was found.

Limited evidence: the Zhizun pivot is central to the bull case (premium mix → margin recovery) but the web has not independently validated that Zhizun has materially gained share or mix in 2024–2025. Historian's question on whether the FY2024 S&M spike actually moved Zhizun volumes remains unanswered by external sources.

Sources: https://aim2flourish.com/innovations/saving-energy-by-concentrating-liquid-laundry-detergent, https://finance.yahoo.com/news/investors-reacting-blue-moon-group-001430421.html

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

Pan Dong (Chairwoman, CTO, 73.78%)

Former organic-chemistry teacher at Wuhan University (BSc + MSc), MBA at Lawrence Technological University (Michigan). Canadian citizen, Hong Kong resident per Forbes. Board chair since 2007; CTO since 1997. Husband Luo Qiuping is the CEO and co-founder. In 2010 she and Luo invited Hillhouse's Zhang Lei into the cap table, whose US$45M investment became the only external pre-IPO institutional stake (Financial Post, 2021). Forbes once listed her net worth at US$8.3B post-IPO; MarketScreener's 2026-03-30 valuation marks the stake at roughly US$1.59B — a ~80% compression in paper wealth alongside the share-price drawdown. No recent personal insider transactions located in search.

Luo Qiuping (CEO, husband of Pan Dong)

Certified chemical engineer, Wuhan University MSc organic chemistry. CEO since 2008-02-12, executive director since 2020-06-22 (pre-IPO formalization). Tenure 18.2 years. FY2024 total compensation HK$7.99M (Simply Wall St: ~US$1.02M, below US large-cap average). No direct shareholding reported on Simply Wall St leadership table (ownership rolled into the Pan Dong 73.78% block via Aquarius-type family vehicles per Sherlock's thesis).

Luo Dong (Executive Director, Chief Supply Officer)

Tenure 20.3 years (joined before Qiuping Luo's formal CEO appointment). Directly holds 1.08% (63.4M shares, ~US$23M). FY2024 total compensation HK$36.82M — the highest-paid individual on the board and 4.6× the CEO. The surname match, co-appointment date (2008-02-11), and compensation outlier suggest a family relationship with CEO Luo Qiuping. The web does not directly confirm this; the FY2025 annual report's related-party section would be the authoritative source.

HHLR Advisors (Hillhouse) — 8.99% outside holder

Hillhouse Capital's public-markets arm (now HHLR Advisors Ltd, run by Lei Zhang). 527.4M shares, ~US$194M. Top 5 positions are PDD / BABA / ONC / FUTU / LEGN per Stockzoa; Blue Moon is a long-standing consumer-staples hold since pre-IPO. Q4 2025 overall portfolio performance −16.42% per Hedgefollow. No reduction in Blue Moon holding reported.

No Results

Note: residual float calculated from 21.15% MarketScreener free float minus identifiable sub-5% insider holdings; small-insider sub-totals estimated.

No Results

Source: https://simplywall.st/stocks/us/household/otc-blum.y/blue-moon-group-holdings/management

Industry Context

China's household-cleaning and laundry-detergent category is mature and moderately growing. Global laundry-detergent forecasts cluster around 4–5% CAGR (Maximize Market Research 3.9% 2026–2032 to US$80.2B; Stellar MR 5.4% 2025–2032 to US$110.9B; Cognitive Market Research). China's liquid-detergent penetration was 44% in 2019 versus 79.5% in Japan and 91.4% in the US (Frost & Sullivan via IPO prospectus), implying further liquid-vs-powder substitution headroom but slow premiumization.

Competitive intensity is high and structural:

Private domestic competitors: Liby (roughly tied with Blue Moon in liquid-detergent share per pre-IPO Frost & Sullivan), Nice Group, Walch, White Cat — none publicly listed, so their financials are not comparable.
Global premium competitors: P&G (Ariel, Tide), Unilever, Kao — gross margins sub-50% vs Blue Moon's historical 60%+, implying the premium margin gap is what Zhizun's concentrate push needs to defend.
Channel economics: China live-streaming e-commerce reached ~RMB 5 trillion in 2023 and is forecast at RMB 8.2 trillion by 2026 (Statista via HI-COM). Top Douyin/Taobao Live KOLs extract 25% commission + 40% discount — the structural reason online channel growth depresses reported margin for premium brands.

HK market context: the HKEX reformed ongoing public float rules effective 2026-01-01 (Rule 13.32B), permitting a 10% / HK$1B alternative threshold. Blue Moon clears both limbs comfortably and faces no immediate float compliance risk — though monthly float reporting is now mandatory.